ES2606173T3 - Composición farmacéutica para el tratamiento y/o la prevención del cáncer - Google Patents

Composición farmacéutica para el tratamiento y/o la prevención del cáncer Download PDF

Info

Publication number
ES2606173T3
ES2606173T3 ES11739881.8T ES11739881T ES2606173T3 ES 2606173 T3 ES2606173 T3 ES 2606173T3 ES 11739881 T ES11739881 T ES 11739881T ES 2606173 T3 ES2606173 T3 ES 2606173T3
Authority
ES
Spain
Prior art keywords
fragment
lys
antibody
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11739881.8T
Other languages
English (en)
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of ES2606173T3 publication Critical patent/ES2606173T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

Un anticuerpo o un fragmento del mismo, en donde el anticuerpo o el fragmento tienen una actividad citotóxica contra una célula cancerosa que expresa una proteína CAPRIN-1 y: (a) se unen a un polipéptido que consiste en la secuencia de aminoácidos representada por la SEQ ID NO: 37; o (b) reconocen un fragmento que consiste en entre 7 y 12 aminoácidos de la secuencia de aminoácidos de la SEQ ID NO: 37, con la condición de que el anticuerpo o el fragmento del mismo no se unan a un polipéptido que consiste en la secuencia de aminoácidos Arg-Asn-Leu-Glu-Lys-Lys-Lys-Gly-Lys-Leu-Asp-Asp-Tyr-Gln o a un fragmento que consiste en entre 7 y 12 aminoácidos de la misma.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27

Claims (1)

  1. imagen1
ES11739881.8T 2010-02-04 2011-02-04 Composición farmacéutica para el tratamiento y/o la prevención del cáncer Active ES2606173T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2010023453 2010-02-04
JP2010023453 2010-02-04
JP2010183161 2010-08-18
JP2010183161 2010-08-18
PCT/JP2011/052412 WO2011096533A1 (ja) 2010-02-04 2011-02-04 癌の治療及び／又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
ES2606173T3 true ES2606173T3 (es) 2017-03-23

Family

ID=44355527

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11739881.8T Active ES2606173T3 (es) 2010-02-04 2011-02-04 Composición farmacéutica para el tratamiento y/o la prevención del cáncer

Country Status (16)

Country Link
US (1) US8937160B2 (es)
EP (1) EP2532366B1 (es)
JP (1) JP5742713B2 (es)
KR (1) KR101801667B1 (es)
CN (1) CN102821789B (es)
AU (1) AU2011211698B2 (es)
BR (1) BR112012018951C8 (es)
CA (1) CA2788716C (es)
DK (1) DK2532366T3 (es)
ES (1) ES2606173T3 (es)
HU (1) HUE030742T2 (es)
MX (1) MX342291B (es)
PL (1) PL2532366T3 (es)
PT (1) PT2532366T (es)
RU (1) RU2597971C2 (es)
WO (1) WO2011096533A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2733223C (en) 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
MX2011001445A (es) * 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
RU2624029C2 (ru) 2010-02-04 2017-06-30 Торэй Индастриз, Инк. Лекарственный препарат для лечения и/или профилактики рака
PT2532365T (pt) 2010-02-04 2016-07-28 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
HUE030742T2 (en) 2010-02-04 2017-06-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
KR101871704B1 (ko) 2010-02-04 2018-06-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
KR101980554B1 (ko) 2011-08-04 2019-05-21 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2013018885A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の検出方法
BR112014002614B1 (pt) 2011-08-04 2022-09-20 Toray Industries, Inc Anticorpo ou um fragmento do mesmo, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
EP2740793B1 (en) 2011-08-04 2017-11-29 Toray Industries, Inc. Drug composition for cancer treatment and/or prevention
EP2740489B1 (en) 2011-08-04 2016-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
ES2672695T3 (es) 2011-08-04 2018-06-15 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
MX363136B (es) * 2012-02-21 2019-03-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) * 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2013125636A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
IN2014KN01715A (es) 2012-02-21 2015-10-23 Toray Industries
PL2832366T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego
CA2869120C (en) 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
JP6244912B2 (ja) 2012-07-19 2017-12-13 東レ株式会社 癌の検出方法
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
AU2017348734A1 (en) 2016-10-28 2019-05-16 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
BR112020019935A2 (pt) 2018-03-30 2021-01-26 Toray Industries, Inc. medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método de tratamento e/ou prevenção do câncer
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
JPWO2021182570A1 (es) 2020-03-12 2021-09-16
JPWO2021182572A1 (es) 2020-03-12 2021-09-16
WO2021182573A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び／又は予防のための医薬品
EP4119160A4 (en) 2020-03-12 2024-04-03 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
US20230165957A1 (en) 2020-03-12 2023-06-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2022270523A1 (es) 2021-06-23 2022-12-29
AU2022298240A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240042416A (ko) 2021-07-27 2024-04-02 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
KR20240041917A (ko) 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
JPWO2023008461A1 (es) 2021-07-27 2023-02-02
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
WO2001032910A2 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
AU4185100A (en) * 1999-04-02 2000-10-23 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2404233A1 (en) 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) * 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR100583331B1 (ko) 2001-05-11 2006-05-26 기린 비루 가부시키가이샤 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는 비인간 동물
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
RU2319709C2 (ru) * 2001-07-17 2008-03-20 Рисерч Дивелопмент Фаундейшн Терапевтические агенты, содержащие проапоптозные белки
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005535290A (ja) * 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
WO2004047728A2 (en) * 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
AU2004235382A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
MXPA06010715A (es) 2004-03-19 2007-05-23 Imclone Systems Inc Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
PE20060287A1 (es) 2004-03-30 2006-05-16 Glaxo Group Ltd INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
CN101141981A (zh) 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
US7858324B2 (en) 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
NZ560976A (en) 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
EP1991701A4 (en) * 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP2010023453A (ja) 2008-07-24 2010-02-04 Seiko Epson Corp 流体噴射装置のメンテナンス方法及び流体噴射装置
CA2733223C (en) * 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
PL2324842T3 (pl) 2008-08-05 2015-08-31 Toray Industries Środek indukujący odporność
MX2011001445A (es) 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
JP2010183161A (ja) 2009-02-03 2010-08-19 Toshiba Corp カメラシステム
PT2532365T (pt) * 2010-02-04 2016-07-28 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
RU2624029C2 (ru) 2010-02-04 2017-06-30 Торэй Индастриз, Инк. Лекарственный препарат для лечения и/или профилактики рака
HUE030742T2 (en) 2010-02-04 2017-06-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
KR101871704B1 (ko) 2010-02-04 2018-06-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
EP2740489B1 (en) 2011-08-04 2016-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
WO2013018885A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の検出方法

Also Published As

Publication number Publication date
MX342291B (es) 2016-09-23
RU2597971C2 (ru) 2016-09-20
JPWO2011096533A1 (ja) 2013-06-13
HUE030742T2 (en) 2017-06-28
WO2011096533A1 (ja) 2011-08-11
BR112012018951B1 (pt) 2020-05-12
US8937160B2 (en) 2015-01-20
EP2532366B1 (en) 2016-09-07
KR101801667B1 (ko) 2017-11-27
US20130045210A1 (en) 2013-02-21
BR112012018951A8 (pt) 2020-03-31
MX2012009000A (es) 2012-08-31
EP2532366A4 (en) 2013-12-04
CA2788716C (en) 2019-06-18
EP2532366A1 (en) 2012-12-12
BR112012018951C8 (pt) 2020-06-23
KR20130033347A (ko) 2013-04-03
JP5742713B2 (ja) 2015-07-01
CN102821789B (zh) 2016-03-02
AU2011211698A1 (en) 2012-08-23
BR112012018951B8 (pt) 2020-06-09
DK2532366T3 (da) 2017-01-02
PT2532366T (pt) 2016-12-20
BR112012018951A2 (pt) 2017-06-27
AU2011211698B2 (en) 2015-07-16
RU2012137504A (ru) 2014-03-10
CN102821789A (zh) 2012-12-12
PL2532366T3 (pl) 2017-02-28
CA2788716A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
ES2606173T3 (es) Composición farmacéutica para el tratamiento y/o la prevención del cáncer
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
ES2541217T3 (es) Diferenciación de células madre mesenquimales
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
IN2014KN01713A (es)
IN2014KN01716A (es)
IN2014KN01714A (es)
ES2666720T3 (es) Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano
UA113712C2 (xx) Антитіло до fap і способи його застосування
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
AR083293A1 (es) Agentes de union a cd33
PE20120586A1 (es) Proteinas de union a il-1
CL2019000681A1 (es) Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk.
AR074219A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
WO2011008823A3 (en) Peptide-mediated non-covalent delivery of active agents across the blood brain barrier
PE20141473A1 (es) Senalizacion slit-robo para el diagnostico y tratamiento de la enfermedad renal
CL2017002233A1 (es) Un factor de coagulación (fvii o fviia) modificado con tres péptidos carboxi terminal de gonadotropina coriónica unidos al carboxi terminal de fvii o fviia; polinucleótido que lo codifica; composición farmacéutica que lo comprende; uso de fvii o fviia modificado para el tratamiento de coagulación de la sangre o un trastorno de coagulación; método para extender la vía media biológica de un factor de coagulación; método para producir dicho fvii o fviia.
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2020003293A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
UY37967A (es) Compuestos y métodos para la reducción de la expresión de snca
CL2020003209A1 (es) Composición de aminoácidos para su uso en la prevención y tratamiento de enfermedades hepáticas
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
CL2021001479A1 (es) Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391)